Neuromyelitis optica spectrum disorder: an overview

被引:5
|
作者
Ramakrishnan, Pooja [1 ]
Nagarajan, Devipriya [1 ]
机构
[1] SASTRA Univ, Sch Chem & Biotechnol, Radiat Biol Lab, Thanjavur, Tamil Nadu, India
关键词
neuromyelitis optica; AQP4; ADCC; CDC; multiple sclerosis; NMOSD; pain; Th17; cytokines; RESONANCE-IMAGING ABNORMALITIES; HELICOBACTER-PYLORI INFECTION; NEUTROPHIL-ACTIVATING PROTEIN; FIBRILLARY ACIDIC PROTEIN; BLOOD-BRAIN-BARRIER; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID; MYASTHENIA-GRAVIS; CLINICAL-FEATURES; T-CELLS;
D O I
10.21307/ane-2020-023
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuromyelitis optica also known as Devic's syndrome is a rare autoimmune disorder that predominantly targets the optic nerves and the spinal cord. It is a debilitating disorder that damages a person's health. Initially it was considered as a variant of multiple sclerosis (MS). But, in 2004, a water channel protein associated antibody was found to be responsible for the disease. This helped in distinguishing the disease from multiple sclerosis. Multiple molecular mechanisms like complement dependent cytotoxicity, antibody-dependent cellular cytotoxicity etc. contribute to the disease. Certain environmental and genetic factors have been identified as risk factors of the disease. Initially, the disease was thought to affect only the optic nerves and the spinal cord. But certain regions of the brain have also been found to be attacked during the course of the disease. A small proportion of the patients have been found to be seronegative for the AQP4-IgG. Recently, the term neuromyelitis optica spectrum disorder has been framed to include all the features of the disease. The disease remains incurable despite the availability of various treatment modalities. This review presents critical information obtained from prior studies regarding the disease and also raise several questions to understand the research gaps in this field.
引用
下载
收藏
页码:256 / 272
页数:17
相关论文
共 50 条
  • [31] Depression in patients with neuromyelitis optica spectrum disorder
    Seok, J. M.
    Choi, M.
    Kim, Y. S.
    Cho, E. B.
    Lee, H. L.
    Kang, S. -Y.
    Lee, K. H.
    Kim, B. J.
    Min, J. -H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 94 - 94
  • [32] Choreoathetosis in a patient with neuromyelitis optica spectrum disorder
    Sugeno, Naoto
    Izumi, Rumiko
    Kato, Kazuhiro
    Nakashima, Ichiro
    Takeda, Atsushi
    Aoki, Masashi
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2013, 1 (04): : 154 - 156
  • [33] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Nie, Tina
    Blair, Hannah A.
    CNS DRUGS, 2022, 36 (10) : 1133 - 1141
  • [34] Hypogeusia as a symptom of neuromyelitis optica spectrum disorder
    Iones, Anna
    Howard, Jonathan
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1548 - 1549
  • [35] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    CNS Drugs, 2022, 36 : 1133 - 1141
  • [36] Neuromyelitis optica spectrum disorder and active tuberculosis
    Grieve, James Kerr
    Day, Scott
    Connell, David
    O'Riordan, Jonathan
    BMJ CASE REPORTS, 2020, 13 (01)
  • [37] Response to "Epidemiology of neuromyelitis optica spectrum disorder''
    Dale, G. H.
    Bacher Svendsen, K.
    Gjelstrup, M. C.
    Christensen, T.
    Houen, G.
    Nielsen, E.
    Bek, T.
    Petersen, T.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (06): : 628 - 629
  • [38] Eculizumab in the treatment of neuromyelitis optica spectrum disorder
    Nabizadeh, Fardin
    Moghadasi, Abdorreza Naser
    CURRENT JOURNAL OF NEUROLOGY, 2023, 22 (02): : 140 - 143
  • [39] Rapidly Progressive Neuromyelitis Optica Spectrum Disorder
    Ghanayem, Tamer G.
    Shah, Varun
    Fang, Xiang
    Shanina, Elena
    ANNALS OF NEUROLOGY, 2020, 88 : S51 - S51
  • [40] Neuromyelitis optica spectrum disorder in Tehran, Iran
    Eskandarieh, S.
    Sahraian, M. A. S.
    Nedjat, S.
    Azimi, A. R.
    Moghadasi, A. N.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 710 - 711